Theramex launches Femarelle to treat menopause symptoms
pharmafile | November 15, 2021 | News story | Sales and Marketing |
Theramex recently announced that they have acquired the Femarelle ® product licence to treat menopause symptoms. The commercialisation agreement was reached with product developer Se-cure Pharmaceuticals Ltd.
Femarelle is a non-hormonal therapy, for balancing oestrogen levels in women from peri-menopause through menopause to post-menopause. It is characterised by the natural compound DT56a, an oestrogen receptor modulator, supplemented with vitamins and minerals that are appropriate for each menopause stage.
The DT56a compound adheres to oestrogen receptors without being recognised as oestrogen by the body. It was declared a “first -line menopause treatment for menopause management” at the Presidential Conference of the Annual Congress of the European Society of Gynaecology in 2017.
“Our main objective is to meet women’s health needs around the world,” said Theramex chief executive Robert Stewart. “Not only their current needs but future ones too in order to improve their lives. With Femarelle®, we are adding to our portfolio an alternative for women with untreated menopause who are reluctant to use hormone therapy.”
Esti Grunbaum, Vice President BD & Marketing at Se-cure Pharmaceuticals Ltd, said: “We are very excited about this collaboration with Theramex. Together we will provide women with more menopausal treatment options.”
Jose Naranjo, Theramex Vice President Marketing, added: “We offer a non-hormonal option to healthcare professionals, backed by scientific studies verifying its safety and efficacy. This allows us to cover an unmet need for these women who will now be heard, understood and have access to a treatment that will provide them with greater adherence and therefore a better quality of life”.
Lina Adams
